Related Experiment Video
Updated: Dec 6, 2025

Author Spotlight: Advancing Allergic Rhinitis Research with Multicolor Immunofluorescence
Published on: September 22, 2023
The Role of Biologics in Chronic Rhinosinusitis With Nasal Polyps
Gayatri B Patel1, Anju T Peters1
1Division of Allergy and Immunology, Department of Medicine, Feinberg School of Medicine, 12244Northwestern University, Chicago, IL, USA.
Abstract:
Biologic therapy is a new treatment option for patients with chronic rhinosinusitis with nasal polyps (CRSwNP). Currently, the only biologic with Food and Drug Administration-approval status for CRSwNP is dupilumab. Several other biologics are likely to be approved for CRSwNP, including mepolizumab and omalizumab, based on their promising phase 3 trial results. The role of biologics in the treatment paradigm requires consideration of multiple factors that have yet to be clearly established. This includes identifying patients most appropriate for biologic therapy while considering long-term safety and cost-effectiveness in the context of patient preferences and goals.
Related Concept Videos
Drugs Used in Lower Respiratory Disorders: Overview
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Drugs Used in Upper Respiratory Disorders: Overview
Antihistamines (e.g., Benadryl) block histamines from binding. Histamines are chemicals released during an allergic reaction in the body. As a...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
COPD: Management Using Bronchodilators and Corticosteroids
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

